Table 1.
Sex-related comparison of clinicopathological characteristics of the 98 gonadotroph tumors included in the study.
| Clinicopathological Characteristics | All Tumors | Males | Females |
p-Value (Males vs. Females) |
|---|---|---|---|---|
| Age at surgery time (years) (n = 98/64/34) | 63 (33–86) | 63 (37–86) | 61 (33–80) | 0.44 |
| Maximal diameter (mm) (n = 98/64/34) | 27 (13–51) | 28 (13–51) | 24 (13–41) | 0.01 |
| Histological subtype (n = 98/64/34) | ||||
| FSH | 21 (21.4%) | 8 (12.5%) | 13 (38.2%) | ND |
| FSH-LH | 73 (74.5%) | 52 (81.25%) | 21 (61.8%) | |
| LH | 4 (4.1%) | 4 (6.25%) | 0 (0%) | |
| Ki67 index (n = 98/64/34) | ||||
| <3 | 84 (85.7%) | 55 (85.9%) | 29 (85.3%) | 0.93 |
| ≥3 | 14 (14.3%) | 9 (14.1%) | 5 (14.7%) | |
| Mitoses (n = 98/64/34) | ||||
| ≤2 | 89 (90.8%) | 60 (93.75%) | 29 (85.3%) | 0.26 |
| >2 | 9 (9.2%) | 4 (6.25%) | 5 (14.7%) | |
| p53 (n = 98/64/34) | ||||
| negative | 60 (61.2%) | 40 (62.5%) | 20 (58.8%) | 0.72 |
| positive | 38 (38.8%) | 24 (37.5%) | 14 (41.2%) | |
| Proliferation (n = 98/64/34) | ||||
| No | 84 (85.7%) | 56 (87.5%) | 28 (82.4%) | 0.48 |
| Yes | 14 (14.3%) | 8 (12.5%) | 6 (17.6%) | |
| Invasion (n = 94/62/32) | ||||
| Yes | 53 (56.4%) | 37 (59.7%) | 16 (50%) | 0.37 |
| No | 41 (43.6%) | 25 (40.3%) | 16 (50%) | |
| Grade (n = 94/62/32) | ||||
| 1a | 35 (37.2%) | 23 (37.1%) | 12 (37.5%) | ND |
| 1b | 6 (6.4%) | 2 (3.2%) | 4 (12.5%) | |
| 2a | 47 (50%) | 32 (51.6%) | 15 (46.9%) | |
| 2b | 6 (6.4%) | 5 (8.1%) | 1 (3.1%) | |
| IRS ERα (n = 98/64/34) | 2.5 (0–12) | 2 (0–12) | 3.5 (0–12) | 0.35 |
| IRS SST2 (n = 97/64/33) | 0 (0–12) | 0 (0–12) | 0 (0–12) | 0.58 |
| IRS SST5 (n = 21/11/10) | 0 (0–0) | 0 (0–0) | 0 (0–0) | ND |
| Complete surgical removal (n = 93/60/33) | ||||
| Yes | 57 (61.3%) | 36 (60%) | 21 (63.6%) | 0.73 |
| No | 36 (38.7%) | 24 (40%) | 12 (36.4%) | |
| Follow-up > 1 year (months) (n = 62/42/20, of which n = 2/1/1 had adjuvant RT) | 43.0 (12.6–88.2) | 46.3 (12.6–88.2) | 37.6 (14.1–69.2) | |
| Relapse or progression > 1 year (n = 60/41/19) | ||||
| Yes | 11 (18.3%) | 8 (19.5%) | 3 (15.8%) | 1 |
| No | 49 (81.7%) | 33 (80.5%) | 16 (84.2%) |
Age at surgery time, maximal diameter, IRS ERα, IRS SST2, IRS SST5, and the follow-up > 1 year are expressed as median with range (applied statistical tests: independent samples t-test for the age at surgery time and Mann–Whitney for the maximal diameter, IRS ERα and IRS SST2; for the rest of the parameters, either Chi-square or Fisher’s exact test were applied, as appropriate). Invasion refers to the radiological invasion. Abbreviations: follicle-stimulating hormone (FSH), luteinizing hormone (LH), number of patients for which the data is available (n), immunoreactive score (IRS), estrogen receptor alpha (ERα), somatostatin receptor (SST), radiotherapy (RT), non-determinable (ND).